Your session is about to expire
What is Signifor
PasireotideThe Generic name of this drug
Treatment SummaryPasireotide, also known as Signifor, is a drug used to treat Cushing's disease. It is a synthetic peptide, similar to a hormone called somatostatin, that works to reduce the amount of hormones in the body that cause Cushing's disease.
Signiforis the brand name
Signifor Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Signifor
Pasireotide
2012
16
Approved as Treatment by the FDA
Pasireotide, also known as Signifor, is approved by the FDA for 2 uses which include Cushing's Disease and Pituitary surgery is not an option or has not been curative .Cushing's Disease
Helps manage Cushing's Disease
Pituitary surgery is not an option or has not been curative
Helps manage Pituitary surgery is not an option or has not been curative
Effectiveness
How Signifor Affects PatientsSignifor® is a medication that helps to lower the amount of cortisol (a hormone) in people with Cushing's disease.
How Signifor works in the bodyPasireotide binds to several somatostatin receptors, which in turn reduces the release of hormones like cortisol, human growth hormone, glucagon, and insulin. This makes it useful for treating conditions like Cushing's disease that involve an overproduction of hormones. Pasireotide is more powerful than somatostatin in blocking the release of these hormones.
When to interrupt dosage
The advised dosage of Signifor is contingent upon the diagnosed condition, including Cushing's Disease, Pituitary surgery is not an option or has not been curative and Acromegaly. The amount of dosage is contingent upon the technique of administration featured in the table beneath.Condition
Dosage
Administration
Cushing's Disease
, 0.3 mg/mL, 0.6 mg/mL, 0.9 mg/mL, 0.3 mg, 0.6 mg, 0.9 mg, 60.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 15.0 mg/mL, 5.0 mg/mL, 30.0 mg/mL, 20.0 mg/mL, 30.0 mg, 10.0 mg/mL
, Subcutaneous, Injection, Injection - Subcutaneous, Kit, Solution, Solution - Subcutaneous, Intramuscular, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
Pituitary surgery is not an option or has not been curative
, 0.3 mg/mL, 0.6 mg/mL, 0.9 mg/mL, 0.3 mg, 0.6 mg, 0.9 mg, 60.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 15.0 mg/mL, 5.0 mg/mL, 30.0 mg/mL, 20.0 mg/mL, 30.0 mg, 10.0 mg/mL
, Subcutaneous, Injection, Injection - Subcutaneous, Kit, Solution, Solution - Subcutaneous, Intramuscular, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
Acromegaly
, 0.3 mg/mL, 0.6 mg/mL, 0.9 mg/mL, 0.3 mg, 0.6 mg, 0.9 mg, 60.0 mg, 40.0 mg, 20.0 mg, 10.0 mg, 15.0 mg/mL, 5.0 mg/mL, 30.0 mg/mL, 20.0 mg/mL, 30.0 mg, 10.0 mg/mL
, Subcutaneous, Injection, Injection - Subcutaneous, Kit, Solution, Solution - Subcutaneous, Intramuscular, Injection, solution, Injection, solution - Subcutaneous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
Warnings
There are 20 known major drug interactions with Signifor.Common Signifor Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Pasireotide.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Pasireotide.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Pasireotide.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Pasireotide.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Pasireotide.
Signifor Toxicity & Overdose RiskOverdosing on this drug can lead to higher than normal blood sugar levels, gallstones, diarrhea, nausea, headaches, abdominal pain, tiredness, and diabetes.
Signifor Novel Uses: Which Conditions Have a Clinical Trial Featuring Signifor?
Thirteen active clinical trials are assessing the potential of Signifor in treating Cushing's Disease, in cases where Pituitary Surgery is not an option or has not been curative, and Acromegaly.Condition
Clinical Trials
Trial Phases
Pituitary surgery is not an option or has not been curative
0 Actively Recruiting
Acromegaly
6 Actively Recruiting
Phase 3, Phase 2, Not Applicable
Cushing's Disease
4 Actively Recruiting
Phase 2, Not Applicable, Phase 1
Signifor Reviews: What are patients saying about Signifor?
3.3Patient Review
1/3/2014 This medication unfortunately gives my mom a lot of fatigue and loose stools, though it does help with her condition.
Patient Q&A Section about signifor
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is Signifor used for?
"SIGNIFOR is a treatment for adult patients with Cushing's disease who cannot have surgery or whose surgery did not cure them."
Answered by AI
How do you inject a Signifor?
"Signifor must be injected deep into a muscle by a trained healthcare professional. The suspension can only be prepared just before it is administered. The site for repeat injections should alternate between left and right gluteal muscles."
Answered by AI
Who makes Signifor?
"Recordati has agreed to acquire the global rights to two of Novartis' medicines, Signifor and osilodrostat. Signifor is used to treat patients suffering from Cushing's disease, while osilodrostat is used to treat patients with Cushing's syndrome and/or adrenal tumors. The acquisition will give Recordati a significant presence in the market for endocrine diseases."
Answered by AI
How is Signifor administered?
"Signifor is to be injected just below the skin by the patient. The patient should receive instructions from the physician or a healthcare professional on how to inject Signifor just below the skin. Injections should not be given in the same spot two times in a row."
Answered by AI